Price T Rowe Associates Inc Uni Qure N.V. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Uni Qure N.V. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 23,300 shares of QURE stock, worth $131,878. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,300
Previous 16,100
44.72%
Holding current value
$131,878
Previous $84,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding QURE
# of Institutions
141Shares Held
33.7MCall Options Held
1.54MPut Options Held
389K-
Vestal Point Capital, LP New York, NY4.75MShares$26.9 Million1.59% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.65MShares$15 Million0.79% of portfolio
-
Black Rock Inc. New York, NY1.93MShares$10.9 Million0.0% of portfolio
-
683 Capital Management, LLC New York, NY1.9MShares$10.8 Million0.78% of portfolio
-
Schroder Investment Management Group London, X01.74MShares$9.85 Million0.01% of portfolio
About uniQure N.V.
- Ticker QURE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,729,100
- Market Cap $264M
- Description
- uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...